Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Aumolertinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Aumolertinib is a once-a-day tablet for non-small cell lung cancer (NSCLC) in adults whose tumour carries a change, or mutation, in the EGFR gene. It was developed and is made in China by Jiangsu Hansoh Pharmaceutical Group Co., Ltd., and is sold there as 阿美乐 (Ameile®). Outside China the brand name is Aumseqa®. Older papers call it almonertinib, its earlier name, and in trials it was coded HS-10296.
China's National Medical Products Administration (NMPA) first approved it in March 2020. It now has five approved uses in China, all for NSCLC with an EGFR mutation:
A laboratory test must confirm the EGFR mutation before treatment starts. It is a prescription targeted cancer treatment and should be started and monitored by an oncologist.
EGFR is a receptor on the surface of cells that tells them when to grow. In some lung cancers a mutation leaves this switch stuck in the "on" position, so the cancer keeps multiplying. This tablet is a third-generation EGFR tyrosine kinase inhibitor. It forms a lasting chemical bond with the faulty receptor, including the common exon 19 deletion and L858R forms and the T790M form that often makes earlier EGFR tablets stop working, while acting more weakly on normal EGFR. Animal studies suggest it can cross into the brain, which matters because lung cancer often spreads there.
The main first-line study, AENEAS, was a phase 3 trial at 54 centres in China. It randomly assigned 429 people with untreated advanced EGFR-mutated NSCLC to this tablet or to an older, first-generation EGFR tablet. In the analysis reviewed by the European Medicines Agency, the median time before the cancer grew was 19.1 months, against 9.7 months with the comparison medicine (hazard ratio 0.46). Responses also lasted longer (a median of 18.1 against 8.3 months). Overall survival was 39.2 against 31.2 months, a difference that was not statistically significant.
A second study enrolled 244 people whose cancer had developed the T790M mutation after an earlier EGFR tablet. In this group, 65.6% saw their tumours shrink, as judged by independent reviewers.
For the after-surgery, after-chemoradiotherapy and chemotherapy-combination uses, your oncologist follows the Chinese prescribing information for the plan and the length of treatment.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
The figures below come from 545 people who took 110 mg a day in the main studies, as summarised in the European assessment report. Most side effects were mild, but a few need quick action.
Other common effects: nose and throat infections (23.3%), skin rash (22.8%), urinary infections (18.3%), cough (15.4%), diarrhoea (13.2%), mouth sores (12.5%), vomiting (10.6%) and itching (10.5%). Compared with the older EGFR tablet in AENEAS, rash and diarrhoea were less frequent, while the CPK rise was more frequent.
Medicines and pregnancy: strong CYP3A4 inhibitors raise its blood level, and moderate or strong CYP3A4 inducers (including some tuberculosis and epilepsy medicines) lower it and are not recommended together. It can also weaken some hormonal contraceptives. Women who could become pregnant should avoid pregnancy during treatment and for 4 weeks after the last dose, using a non-hormonal method or adding a barrier method such as condoms. Safety in people under 18 has not been established. Always share a full list of your medicines and supplements with the oncologist.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Supply is arranged for one named patient, through the patient or the treating hospital, under India's rules for importing unapproved medicines. We usually ask for:
Once the prescription and test reports have been checked and, where needed, the import permit is in place.
Not yet. It has no marketing approval from CDSCO and cannot be bought from an Indian chemist. An Indian company has applied for permission to market it, but in 2026 the expert committee asked for more data, including a study in Indian patients, before it can be considered. It is not approved by the US FDA. It is approved in the United Kingdom (MHRA, June 2025). In the European Union it was approved in February 2026, but that licence was revoked in September 2026 over a data-protection point in the original filing, which the company describes as procedural. After a new application, the EMA's committee again recommended approval on 12 November 2026, and the final European decision is pending.
Until it is registered here, the Named Patient Program (NPP) offers a lawful route for one patient to import it on a doctor's prescription. We also help families with other China-approved EGFR tablets for lung cancer, such as befotertinib and rezivertinib for T790M-positive disease.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The European assessment of the 55 mg tablet set storage at no more than 30°C in the original container, protected from moisture. For the Chinese packs we follow the instructions printed on the box, and the sealed cartons travel under temperature-controlled shipping. At the usual dose of two tablets a day, a month of treatment needs about 60 tablets, so we plan each shipment to cover a full month or more. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Treatment with an EGFR tablet often continues for many months, so we plan a steady supply. After the oncologist's prescription and the EGFR report are checked and the import papers are ready, the tablets can reach the cities below and most other parts of the country.
Chest and cancer specialists in Delhi see many patients with EGFR-positive lung cancer, and dispatch from New Delhi keeps delivery within the city quick.
Families in Mumbai can send the EGFR test report and prescription together, and we confirm which paperwork the import needs before quoting.
For patients in Bangalore taking the tablets at home, we schedule deliveries so the next month's supply arrives before the current box runs out.
Oncologists in Chennai who have a confirmed T790M test result can request the tablets for a named patient.
Patients in Hyderabad receive a written cost estimate first, and the order is placed only after the family agrees.
A caregiver in Kolkata or the north-east gets a message with the courier details as soon as the month's tablets leave our dispatch desk.
Patients in Pune who are moving on to the tablet after surgery or chemoradiotherapy can use the same documented import route.
The treating doctor in Ahmedabad can begin the request by sharing the biopsy and mutation reports with our team.
In Vellore, where many patients come for scans and EGFR testing, the boxes can be sent to the hospital pharmacy ahead of the follow-up appointment.
We deliver through Chandigarh to patients and hospitals in Punjab, Haryana and Himachal Pradesh.
For patients in Lucknow and the rest of Uttar Pradesh, the family can pick home delivery or delivery to the chest oncology clinic.
Kerala patients on long-term treatment usually take a monthly parcel at Kochi, Kottayam or a town near home.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message